Article
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2021
Wislez Marie, Domblides Charlotte, Greillier Laurent, Mazières Julien, Monnet Isabelle, Kiakouama-Maleka Lize, Quantin Xavier, Spano Jean Philippe, Ricordel Charles, Fraisse Philippe, Janicot Henri, Audigier-Valette Clarisse, Amour Elodie, Langlais Alexandra, Rabbe Nathalie, Makinson Alain, Cadranel Jacques, Laurent-Puig Pierre, Lavolé Armelle, Blons Hélène
Abstract excerpt
INTRODUCTION: HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA's prognostic value in PLHIV from a dedicated phase II trial. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.